CVT-313 (CAS 199986-75-9) is a potent inhibitor of cyclin-dependent kinase 2 (CDK2) an enzyme essential for G1/S transition during cell cycle progression By targeting CDK2 CVT-313 effectively reduces hyperphosphorylation of retinoblastoma protein (Rb) leading to cell cycle arrest at the G1/S boundary In vitro studies with MRC-5 fibroblasts demonstrated significant growth inhibition Additionally CVT-313 induces apoptosis in diffuse large B-cell lymphoma by diminishing phosphorylation of Rb at T821 and downregulating anti-apoptotic protein Mcl-1 In animal models of arterial restenosis CVT-313 significantly reduces neointimal proliferation indicating potential utility for proliferative disorders research